European Disease Progression Monitor: Edition 5

European Disease Progression Monitor: Edition 5

COVID-19 EU progression monitor

lockdown exit strategies in EU

lockdown transition plan

COVID-19 death rate EU

tracking the pandemic

control phase

French data

U.K. numbers have stabilised

Overview of treatments

Disclaimer

For more information, please visit lek.com/covid19 or fill out this form to get in touch.

Other editions in this series:
European Disease progression monitor: Edition 4

Related Insights

Organization & Performance

Published Articles

How Not If: Remote Working and the ‘Next Normal’

May 18, 2020

In this article we review a range of potential remote working operating models and summarise our analytical framework for quantifying and assessing how…

Organization & Performance

Published Articles

Workers’ desire to work from home grows as lockdown continues

May 22, 2020

New survey shows even more people than in April (now 60%) want to commute less after the COVID crisis, as new working practices become normal.

Life Sciences & Pharma

Executive Insights

European Drug Pricing and Market Access in a COVID-19 World

October 14, 2020

On 3 June 2020, Médecins Sans Frontières (MSF) issued an appeal urging world leaders to ensure that pharmaceutical companies sell any COVID-19 vaccines at…

Life Sciences & Pharma

Presentations

COVID-19 Implications for Asia-Pacific Healthcare Ecosystems

May 14, 2020

It is essential for healthcare ecosystem stakeholders across APAC to leverage opportunities that have arisen and prepare for the new norm.

Life Sciences & Pharma

Presentations

European Disease Progression Monitor: Edition 7

May 26, 2020

The COVID-19 Disease Progression Monitor delivers evidence on the effects of the disease on services, systems and therapies across the Life Sciences and…

Life Sciences & Pharma

Presentations

COVID-19 Therapeutic Research and Development Landscape

June 3, 2020

The following materials provide a snapshot of the unprecedented scope and speed of biopharma’s therapeutics research and development (R&D) response to…